NIPT
Yourgene Health Q1 Preliminary Revenues Rise 80 Percent
The company also reported a 10 percent increase in fiscal year 2021 revenues, in line with its unaudited results.
Progenity, Natera Jointly Request Dismissal of Patent Litigation
Progenity sought a declaratory judgment from a California court last year that its Innatal NIPT test didn't infringe six patents held by Natera.
The genetic testing and health intelligence firm will start trading on the Nasdaq Global Select Market on Friday under the ticker symbols SMFR and SMFRW.
Natera Inks Distribution Deal With TomaLab for Italy
The deal covers three of Natera's tests including its Signatera circulating tumor DNA test for cancer treatment monitoring and minimal residual disease assessment.
The company believes its molecular counting technology can offer improved sensitivity for advanced cancer genotyping and longitudinal monitoring of response to therapy.
Jun 14, 2021
BillionToOne Raises $55M in Series B Financing
May 26, 2021
Illumina, Roche Agree to Settle NIPT Patent Lawsuits
Apr 14, 2021
Feb 25, 2021
Natera Revenues Grow 35 Percent in Q4
Nov 9, 2020
Progenity Q3 Revenues Increase 38 Percent
Oct 26, 2020